The Commerce Commission has brought 10 charges against Reckitt Benckiser, the maker of Nurofen, over the packaging of four pain-relief products.
The charges, under the Fair Trading Act, relate to the packaging and advertising of:
- Nurofen Migraine Pain
- Nurofen Tension Headache
- Nurofen Period Pain
- Nurofen Back Pain
The commission alleges the manufacturer's website and the products' packaging gave the overall impression that the products were targeted to provide relief for a specific kind of pain. The products are identical and contain the same amount of active ingredient, 342mg of ibuprofen lysine.
Reckitt Benckiser changed its packaging of the products in March after signing court enforceable undertakings with the commission. It was fined AU$1.7 million in Australia in April after the Federal Court found it had engaged in misleading conduct in its marketing of the Nurofen Specific Pain products. The Australian Competition and Consumer Commission has filed an appeal as it believes the company should have been fined at least $6 million. A hearing has been scheduled for November.
In a statement issued today, Nurofen NZ said the range was launched "to provide easy navigation of pain-relief within the grocery environment where pharmacy support is not available".